Wearable mixed-reality devices have become a hot topic of conversation among technology professionals–but also among creatives—in the weeks since Meta announced the Orion AR glasses.

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales of drugs like breast-cancer treatment Kisqali. The Swiss pharmaceutical ...

LOS ANGELES -- Since 2001, the Disney Television Discovers: Talent Showcase has been a vital force in the entertainment industry. More than 600 performers have had their careers launched by the ...

This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) ...

THE Intellectual Property Office of the Philippines (IPOPHL) is set to release guidelines on creative works generated with artificial intelligence (AI). According to IPOPHL Director General Rowel ...

This unit is taught by a STEM academics who have worked in a creative industries setting. Natural language processing for the creative industries This practical class develops key coding skills to ...

Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing authorization ...

EMA's CHMP issued a positive opinion for Novartis' Kisqali for high-risk early breast cancer. Kisqali showed a 25.1% reduced risk of cancer recurrence in Phase 3 NATALEE trial. The CHMP ...

Novartis said the European Medicines Agency has recommended its Kisqali cancer drug for market authorization. The drugmaker said Friday that the EMA's Committee for Medicinal Products for Human ...

“If approved, Kisqali could provide an effective and tolerable adjuvant treatment option to mitigate the risk of recurrence in a broader patient population, particularly for patients who ...